D. E. Shaw & Co., Inc. Janux Therapeutics, Inc. Put Options Transaction History
D. E. Shaw & Co., Inc.
- $122 Billion
- Q4 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding JANX
# of Institutions
227Shares Held
55.1MCall Options Held
687KPut Options Held
357K-
Ra Capital Management, L.P. Boston, MA10.4MShares$384 Million8.99% of portfolio
-
Janus Henderson Group PLC London, X03.56MShares$132 Million0.1% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.52MShares$130 Million7.18% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.06MShares$114 Million0.3% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$86.9 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.55B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...